Network origin in Toshinobu Iwasaki first degree
Entity | Entity type | Industry | |
---|---|---|---|
Shionogi Ltd.
Shionogi Ltd. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi Ltd. is a British company that manufactures and distributes pharmaceutical products. The company is based in London, UK.
2
| Subsidiary | Pharmaceuticals: Major | 2 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Toshinobu Iwasaki via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
INCYTE CORPORATION | Pharmaceuticals: Major | Corporate Officer/Principal | |
The Johns Hopkins University | College/University | Undergraduate Degree | |
Rutgers State University of New Jersey | College/University | Doctorate Degree | |
Smithkline Beckman Corp
Smithkline Beckman Corp Pharmaceuticals: MajorHealth Technology Part of GSK Plc, Smithkline Beckman Corp is a company that manufactures pharmaceutical products. The company is based in Philadelphia, PA. Smithkline Beckman was acquired by Smithkline Beecham Plc on July 27, 1989 for $16,082.37 million. | Pharmaceuticals: Major | Corporate Officer/Principal | |
GSK Equity Investments Ltd.
GSK Equity Investments Ltd. Investment ManagersFinance GSK Equity Investment Ltd (GSK Equity) is a venture capital firm a subsidiary of GlaxoSmithKline Plc founded in 1985. The firm is headquartered in Reedwood City, California. | Investment Managers | Private Equity Investor | |
Shionogi, Inc.
Shionogi, Inc. Pharmaceuticals: MajorHealth Technology Part of Shionogi & Co., Ltd., Shionogi, Inc. is a pharmaceutical company based in Florham Park, NJ. Since 1878, the company has been utilizing science to address health challenges and has discovered several novel antibiotics and medications for HIV and influenza. Shionogi conducts ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. The company is committed to pursuing discovery through partnerships, including collaboration with scientists through investigator-initiated research. Shionogi is dedicated to advancing the greater good by developing, partnering, and commercializing medicine to treat serious unmet medical needs in infectious disease and other areas of high medical need including neurology and cardiovascular disease. Nathan McCutcheon has been the CEO of the company since 2019. | Pharmaceuticals: Major | Chief Executive Officer | |
ViiV Healthcare Ltd.
ViiV Healthcare Ltd. Pharmaceuticals: MajorHealth Technology ViiV Healthcare Ltd. manufactures and distributes pharmaceutical products. Its medicine include Triumeq, Tivicay, Selzentry, Celesentri, Epzicom, Kivexa, Ziagen, Trizivir, Combivir, Retrovir AZT, Lexiva, Telzir, Viracept and Rescriptor. The company was founded in 2009 and is headquartered in Brentford, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal |
Statistics
International
United States | 8 |
United Kingdom | 3 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Finance | 2 |
Operational
Director/Board Member | 5 |
Corporate Officer/Principal | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Private Equity Investor | 1 |
Most connected contacts
Insiders | |
---|---|
John Apeler Keller | 10 |
Koji Hanasaki | 1 |
- Stock Market
- Insiders
- Toshinobu Iwasaki
- Company connections